PROTAC using an alt. E3 ligase; plus lung-targeted mRNA COVID vaccine and more

A team including Nathanael Gray from Stanford University, Taebo Sim from Korea University and Ha-Soon Choi from Magicbullettherapeutics Inc. reported in Cell Chemical Biology a bivalent proteolysis targeting chimera (PROTAC), KYH1872, that can induce proximity between ubiquitin E3 ligase KLHDC2 and target kinases to induce degradation of them.

Most degraders utilize E3 ligases CRBN or VHL, but there are 600 E3 ligases in the human genome and adding others to the degrader toolbox could enable degradation of a wider range of targets...